FindTrial
Sign In

Octreotide versus octreotide plus terlipressin in control of acute gastro-oesophageal variceal bleeding

Octreotide versus octreotide plus terlipressin in control of acute gastro-oesophageal variceal bleeding

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015012
Enrollment
Unknown
Registered
2018-02-28
Start date
2018-02-28
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis

Interventions

group A:Octreotide
group B:octreotide plus terlipressin

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. live cirrhosis diagnosed by previous radiologic, laboratory findings or liver biopsy; 2. arrival at the hospital within 24 hours after the occurrence of hematemesis and/or melena; 3. aged between 20 and 75years; 4. patients agree to participate in this tria.

Exclusion criteria

Exclusion criteria: (1) a history of endoscopic variceal therapy within 2 weeks before the episode; (2) advanced hepatocellular carcinoma (HCC) invading portal vein or other malignancy; (3) a history of severe cardiovascular disease, including severe hypertension acute myocardial infarction or congestive heart failure; (4) chronic renal failure; (5) refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
hemoglobin;—

Secondary

MeasureTime frame
vital signs;—

Countries

China

Contacts

Public ContactWandong Hong

The First Affiliated Hospital of Wenzhou Medical University

xhnk-hwd@163.com+86 13868465258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026